Post on 24-Aug-2019
1
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
May 11th , 2015
2
• One of the LEADING health care companies
• Eighth largest pharmaceutical company
• Sixth largest Biotech company
• More than 250 operating companies in 60 countries
• Products are offered in 175 countries
• More than 129.000 employees
MEDICAL DEVICES & DIAGNOSTICS
CONSUMER
PHARMACEUTICALS
Revenue 2013: 71,3 bn $ U.S.
Johnson & Johnson: A leading global health care company.
3
Janssen Company Profile
Who We Are
Last updated: March 2015
One of the LEADING PHARMACEUTICAL RESEARCH COMPANIES
Founded in 1953 in GERMANY since 1959 PART OF JOHNSON & JOHNSON since 1961 years
62 Employees around the world: Approx. 40,000 Approx. 800 in Germany
2014 sales: Approx. EUR 26.6 BIL.
EUR1.04 BIL. in GERMANY
Key therapeutic areas: INFECTIOUS DISEASES IMMUNOLOGY ONCOLOGY NEUROLOGY/PSYCHIATRY
4 ACTIVE COMPOUNDS on the WHO LIST OF ESSENTIAL MEDICINES
6
research and development centers, 8 Production sites IN EUROPE 10
Active on
5 continents
4
Janssen Company Profile
Our Key Therapeutic Areas
Neurology Psychiatry Oncology Immunology Infectious
Diseases
ADHD
Dementia
Epilepsy
Schizophrenia
Pain
Anemia in cancer patients
Multiple myeloma Prostate cancer Breast cancer Ovarian cancer
Acute myeloid leukemia Castleman disease Chronic lymphoid
leukemia Mantle cell lymphoma
Asthma
Psoriasis
Psoriatic arthritis
Hepatitis C
HIV/AIDS
Tuberculosis
5
Our Identity
In the Tradition of Our Founder
“Time is precious, we are running out of it, and the patients are waiting.” Dr. Paul Janssen (1926 – 2003)
2002 2012 2002 2012
16%
33%
20%
50%
Top 10 Pharmaceutical
companies Source: Medtrack; Johnson & Johnson The Wall Street Journal
External Innovation Percentage of drugs under development that were initially developed at another company
• Medical need and differentiation
• Deep scientific and medical expertise
• Select the best science – internal and external
• Excellence in global execution
• Speed to market
Our R&D Strategy: Focus on Transformational Innovation that Solves Unmet Medical Need
Our Approach to Sourcing Innovation
8
Early Exploration
Discovery Concept
Early Development
Late
Development Regulatory Post Launch
Appr
oval
Innovation Centres Business Development
Johnson & Johnson Development Corporation
Internal Discovery &
Early Research
Biomarkers, Research
Capabilities Global
Development
We Find the Best Science "The world is our lab"
9
Licensing & Acquisitions
External Collaborations • Academia • Biotech • Pharma • Consortia
Internal Research
Innovation Center Satellite
Boston
San Diego
California London
Israel
Russia
Australia
Shanghai
Singapore
Japan
Innovation is everywhere, but mostly outside of our own organization
11
Extending Network through Local Scouts
Innovation Centers:
• Local Scouts reach out to extend coverage in several European countries
• Scanning for opportunities and liaising with biotech & academia and maintaining interactions with partner organizations
(Israel)
(Moscow)
Our Janssen Pharmaceutical business is one of the most productive and innovative in the world. In the past 10 years, we have brought more differentiated pharmaceutical products to patients than any other company. The teams at the Johnson & Johnson Innovation Centers are interested in exploring early stage therapeutic and vaccine technologies up to clinical proof of concept in the following areas:
Pharmaceuticals
12
Cardiovascular and Metabolism • Type 2 Diabetes • Heart Failure
Immunology • Rheumatoid
Arthritis • Inflammatory
Bowel Disease • Psoriasis • Pulmonary
Infectious Diseases and Vaccines • Hepatitis • Respiratory
Infections
Neuroscience • Mood Disorders • Alzheimer’s
Disease • Pain
Oncology • Prostate Cancer • Lung Cancer • Hematologic
Malignancies • Colorectal Cancer
What We Consider & How We Prioritize
13
• Conviction level of experts in science & target • Ability to establish pre-clinical and clinical POC • Time and cost to preclinical and clinical POC • Leadership potential (competitive landscape) • Strategic fit for J&J • IP strength • Collaboration capability of partner • Patient impact (medical need) • Societal impact (e.g. patient years) • Transformative potential at time of launch • Cost of access (deal terms)
Delivering Clinical
POC products
POC Proof of Concept
Co-creation Model
14
Innovator Product Idea
Investment
Expertise
Faci
litie
s (L
abs,
offi
ces)
R
&D
ca
pabi
litie
s
J&J Innovation
Centers providing
access to..
Advancing innovative products by enabling access to a full range of incubation ‘ingredients’
supplied by network of strategic partners
Products for
Patients
Right Opportunity
– Ideas / Concepts – Scientific Methods – Technologies +
Tools – Diagnostics – Pharmaceuticals – Consumer Products – Medical Devices
Partnership Model: Flexible and Custom
From
transformational ideas through clinical proof of concept
Right Solution
– Janssen Labs or Janssen Labs@
– Advice + Mentorship – Partnering Offices: J&J
Innovation@ – J&J Innovator & EIR Program – Incubation & Seed Financing – Venture Financing – Investment Partners – Strategic LP Relationships – R&D Collaborations – Soft and Call Options – Licensing – Acquisition
Strategically aligned J&J Innovation areas of focus
Catalyzing innovation at Johnson & Johnson is about creating strong networks of people who can combine resources, ideas and technologies in a new way.”
“
Paul Stoffels, MD Chief Scientific Officer
17
Thank you – Questions? Dr. Klaus Suwelack +49 172 413 670 2 ksuwelac@its.jnj.com www.jnjinnovation.com